Turning Patient Data into Decision‑Ready Evidence

Many clinical teams approach clinical outcome assessments (COAs) with healthy skepticism. They worry about added burden, longer timelines, or unclear return.

But in practice, the real risk is not in the collection of COA data. The risk comes from collecting data that doesn’t ultimately answer the questions that matter most to regulators, payers, or the patients the therapy is intended to help.

The hidden risk of “business as usual”

Today, most development programs already include patient‑focused data, often through COAs or other assessments added early in protocol design. On paper, this can create a sense of confidence, that “we’re measuring the patient’s experience, so we have met the requirement”.

The problem is that measuring the patient’s experience with COAs doesn’t necessarily mean that you are capturing data that properly informs key decisions.  A robust strategy can address this issue.

We frequently see late‑stage programs where:

• Data is collected with COAs, but is poorly aligned to the target patient’s experience
• The COA endpoints included do not support product value differentiation
• COA results cannot be interpreted as meaningful benefit for the patient
• Teams only discover evidence gaps when it’s too late to course‑correct (e.g. during regulatory review or when preparing for launch)

In those moments, the question isn’t “Do we have patient data?”, it’s “Does the data actually support our decisions and claims?”.

A real‑world example: uncovering risk before it’s too late

In one Phase III oncology program, a sponsor was already collecting COA data (in the form of patient reported outcomes, or PROs) in their program. But when the team started to work on expanding their indication, they stepped back to evaluate whether the PRO instruments selected for the previous indication reflected what mattered most to patients in this new indication, the answer wasn’t clear. Critical symptoms and impacts were either under‑represented or missing altogether.

By including a patient‑informed conceptual model and conducting a structured gap analysis, the team was able to:

• Identify misalignment between patient experience and trial endpoints
• Prioritize the concepts that truly mattered to patients
• Gain confidence that the evidence being generated will support patient-relevant value differentiation

The benefit of this work was to reduce the risk of misalignment with regulatory decision makers, and maximize ability to differentiate at launch, before regulatory reviews or commercial launch were on the line.

The value of a thoughtful COA strategy

When COAs are thoughtfully planned:

• Clinical teams gain clarity on which outcomes should be prioritised
• Stakeholder discussions (e.g. regulators, payers) are grounded in patient relevance
• Internal stakeholders can make robust, evidence‑based decisions
• Sponsors are better positioned to differentiate their therapy meaningfully

Just as importantly, teams often discover that they don’t need more patient data, instead they need a better COA strategy.

A practical starting point

Seeing the value of COAs doesn’t always require reinventing a program or developing a new instrument from scratch. Often, the most impactful first step is simply asking:

Are we confident that what we’re measuring truly reflects patient benefit, and will it matter when decisions are made?

Answering that question early can prevent costly surprises later.

Bottom line

COAs are not just about “ticking the box”. When well-planned, COAs deliver confidence that the patient voice captured in a trial is meaningful, defensible, and ready to support the decisions that define success.

Collaborating with IQVIA PCS can enhance your clinical trials by delivering precise representations of patient experiences and offering valuable insights. Our team offers tailored COA strategy solutions designed to enhance the quality of your measurement strategies, empowering you to confidently demonstrate patient benefit.

Reach out to IQVIA PCS’ Livia Lai or Matthew Blowfield to discover how we can support your goals and drive meaningful outcomes in your clinical development programs. For more information, visit https://bit.ly/IQVIA-PCS or contact us.